Journal article
Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study
Abstract
AIM: To investigate the impact of PD-L1 expression status on consolidative durvalumab efficacy and safety in stage III NSCLC patients.
METHODS: This retrospective, ethics board approved, multi-centre study included all patients with histologically and/or cytologically confirmed unresectable stage III NSCLC, EGFR/ALK wild-type patients who completed concurrent chemoradiation therapy (cCRT) from January 2018 to August 2020 at the Cancer Centre of …
Authors
A K; H S; W H; As F; P W-P; A R
Journal
Cancer Treatment and Research Communications, Vol. 29, ,
Publisher
Elsevier
Publication Date
2021
DOI
10.1016/j.ctarc.2021.100496
ISSN
2468-2942